Description:
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with
relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts
(Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and
extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.
Title
- Brief Title: Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
- Official Title: A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
Clinical Trial IDs
- ORG STUDY ID:
RXDX-101-03
- SECONDARY ID:
CO40778
- NCT ID:
NCT02650401
Conditions
Interventions
Drug | Synonyms | Arms |
---|
Entrectinib | RXDX-101 | Any participant unable to swallow capsules |
Purpose
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with
relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts
(Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and
extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.
Trial Arms
Name | Type | Description | Interventions |
---|
Extracranial solid tumors harboring NTRK1/2/3, | Active Comparator | Arm closed for further enrollment
ROS1, ALK non-gene fusion molecular alterations
Oral entrectinib (RXDX-101) | |
CNS tumors harboring- NTRK1/2/3, ROS1, ALK | Active Comparator | Arm closed for further enrollment
molecular alterations, including gene fusions
Oral entrectinib (RXDX-101) | |
Neuroblastoma | Active Comparator | Arm closed for further enrollment
Oral entrectinib (RXDX-101) | |
Non-neuroblastoma, extracranial solid tumors | Active Comparator | Arm closed for further enrollment
harboring - NTRK1/2/3, ROS1, ALK gene fusions
Oral entrectinib (RXDX-101) | |
Any participant unable to swallow capsules | Active Comparator | Arm closed for further enrollment
Any participant who otherwise meet all other eligibility criteria
Oral entrectinib (RXDX-101) | |
Expansion: CNS tumors harboring NTRK1/2/3, ROS1 | Active Comparator | gene fusions
Oral entrectinib (RXDX-101) | |
Expansion: Extracranial solid tumors harboring NTRK1/2/3, ROS1 | Active Comparator | NTRK 1,2,3 and ROS1 fusions
Oral entrectinib (RXDX-101) | |
Eligibility Criteria
Inclusion Criteria:
1. Disease status:
- Phase 1 portion (closed): Participants must have measurable or evaluable disease,
as defined by RECIST v1.1
- Phase 2 portion:
- Part B: Participants must have measurable or evaluable disease, as defined
by RANO
- Part C (closed): Participants must have measurable or evaluable disease, as
defined by RECIST v1.1 ± Curie Scale
- Part D: Participants must have measurable or evaluable disease, as defined
by RECIST v1.1
- Part E (closed): Participants must have measurable or evaluable disease, as
defined by RECIST v1.1 ± Curie Scale or RANO
2. Tumor type:
- Phase 1 portion:
* Part A: Relapsed or refractory extracranial solid tumors
- Phase 2 portion
- Part B: Primary brain tumors with NTRK1/2/3 or ROS1 gene fusions; gene
fusions are defined as those predicted to translate into a fusion protein
with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant
second oncodriver as determined by a nucleic acid-based diagnostic testing
method
- Part D: Extracranial solid tumors (including NB) with NTRK1/2/3 or ROS1 gene
fusions; gene fusions are defined as those predicted to translate into a
fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a
concomitant second oncodriver as determined by a nucleic acid-based
diagnostic testing method
3. Histologic/molecular diagnosis of malignancy at diagnosis or the time of relapse
4. Archival tumor tissue from diagnosis or, preferably, at relapse
5. Performance status: Lansky or Karnofsky score ≥ 60% and minimum life expectancy of at
least 4 weeks
6. Prior therapy: Participants must have a disease that is locally advanced, metastatic,
or where surgical resection is likely to result in severe morbidity, and who have no
satisfactory treatment options for solid tumors and primary CNS tumors that are
neurotrophic tyrosine receptor kinase (NTRK) or ROS1 fusion-positive
7. Participants must have recovered from the acute toxic effects of all prior
chemotherapy, immunotherapy, or radiotherapy prior to enrollment
8. Adequate organ and neurologic function
9. Females of childbearing potential must have a negative serum pregnancy test during
screening and be neither breastfeeding nor intending to become pregnant during study
participation. Agreement to remain abstinent or use use combined contraceptive methods
prior to study entry, for the duration of study participation and in the following 90
days after discontinuation of study treatment.
10. For male participants with a female partner of childbearing potential or a pregnant
female partner: Agreement to remain abstinent or use a condom during the treatment
period and for at least 3 months after the last dose of study drug
Exclusion Criteria:
1. Receiving other experimental therapy
2. Known congenital long QT syndrome
3. History of recent (3 months) symptomatic congestive heart failure or ejection fraction
≤50% at screening
4. Known active infections
5. Familial or personal history of congenital bone disorders, bone metabolism alterations
or osteopenia
6. Receiving Enzyme Inducing Antiepileptic Drugs (EIAEDs) within 14 days of first dose.
7. Prior treatment with approved or investigational TRK or ROS1 inhibitors
8. Known hypersensitivity to entrectinib or any of the other excipients of the
investigational medicinal product
9. Patients with NB with bone marrow space-only disease
10. Incomplete recovery from acute effects of any surgery prior to treatment.
11. Active gastrointestinal disease or other malabsorption syndromes that would impact
drug absorption.
12. Other severe acute or chronic medical or psychiatric condition or lab abnormality that
may increase the risk associated with study participation, drug administration or may
interfere with the interpretation of study results.
Maximum Eligible Age: | 18 Years |
Minimum Eligible Age: | N/A |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Maximum Tolerated Dose (MTD) |
Time Frame: | Approximately 6 months |
Safety Issue: | |
Description: | Assessed by National Cancer Institute Common Terminology for Adverse Events Criteria (NCI CTCAE v4.03) |
Secondary Outcome Measures
Measure: | Safety and Tolerability - AE, ECG and Labs assessed by NCI CTCAE v4.03 |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | AE, ECG and Labs assessed by NCI CTCAE v4.03 |
Measure: | Maximum observed plasma drug concentration (Cmax) using F1 Formulation |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | Maximum observed plasma drug concentration (Cmax) using F06 Formulation given intact |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | Maximum observed plasma drug concentration (Cmax) using F06 Formulation administered via feeding tube |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | Maximum observed plasma drug concentration (Cmax) using minitablets/F15 |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | Time to Cmax, by inspection (Tmax) using F1 Formulation |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | Time to Cmax, by inspection (Tmax) using F06 Formulation given intact |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | Time to Cmax, by inspection (Tmax) using F06 Formulation administered via feeding tube |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | Time to Cmax, by inspection (Tmax) using minitablets/F15 |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | AUC at steady state (AUCss) using F1 Formulation |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | AUC at steady state (AUCss) using F06 Formulation given intact |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | AUC at steady state (AUCss) using F06 Formulation administered via feeding tube |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | AUC at steady state (AUCss) using minitablets/F15 |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | Terminal half life (t½) using F1 Formulation |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | Terminal half life (t½) using F06 Formulation given intact |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | Terminal half life (t½) using F06 Formulation administered via feeding tube |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | Terminal half life (t½) using minitablets/F15 |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | Area under the drug concentration by time curve (AUC) using F1 Formulation |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | Area under the drug concentration by time curve (AUC) using F06 Formulation given intact |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | Area under the drug concentration by time curve (AUC) using F06 Formulation administered via feeding tube |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | Area under the drug concentration by time curve (AUC) using minitablets/F15 |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Measure: | Progression-free Survival (PFS) |
Time Frame: | Approximately 6 months |
Safety Issue: | |
Description: | Defined as time from the date of study enrollment to the first occurrence of objective disease progression or date of death due to any cause, whichever occurs first |
Measure: | Overall Survival (OS) |
Time Frame: | Approximately 6 months |
Safety Issue: | |
Description: | Assessed by RECIST v1.1 |
Measure: | Duration of Response (DOR) |
Time Frame: | Approximately 6 months |
Safety Issue: | |
Description: | Assessed by RECIST v1.1 |
Measure: | Time to response (TTR) |
Time Frame: | Approximately 6 months |
Safety Issue: | |
Description: | Assessed by RECIST v1.1 |
Measure: | Clinical Benefit Rate (CBR) |
Time Frame: | Approximately 6 months |
Safety Issue: | |
Description: | Assessed by RECIST v1.1 |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Hoffmann-La Roche |
Trial Keywords
- TRK
- Tyrosine kinase
- NTRK
- NTRK1
- NTRK2
- NTRK3
- ROS1
- ALK
- Pediatric
- Relapsed
- Refractory
- Solid Tumor
- Metastatic Cancer
- Gene rearrangement
- Neuroblastoma
- Infantile fibrosarcoma
- Secretory breast cancer
- Congenital mesoblastic nephroma
- Pontine glioma
- Brain tumors
- CNS tumors
- Sarcoma
- Ewing sarcoma
- Glial tumors
- Salivary Gland Cancer (MASC)
- Papillary thyroid cancer
- Medulloblastoma
- Wilms tumor (anaplastic)
Last Updated
August 17, 2021